Quantcast

Latest Auxilium Pharmaceuticals Inc. Stories

2014-07-31 16:29:32

-Company to Host Conference Call That Day at 8:30 a.m. ET- CHESTERBROOK, Pa., July 31, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the Company will release results for the second quarter of 2014 on Thursday, August 7, 2014 before the opening of the U.S. financial markets. The Company also will conduct a conference call that day at 8:30 a.m. ET to discuss results and highlights of the...

2014-07-31 08:34:32

Acceptance of Regulatory Submission Triggers $10 Million Milestone Payment to Auxilium CHESTERBROOK, Pa., July 31, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Company will receive a $10 million regulatory milestone payment from its partner Asahi Kasei Pharma Corporation (Asahi Kasei). The payment is due because of the successful submission of a regulatory application to the Japanese Pharmaceutical...

2014-06-30 12:32:44

NEW YORK, June 30, 2014 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of Auxilium Pharmaceuticals Inc. ("Auxilium" or "the Company") (NasdaqGS: AUXL) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to QLT Inc. (NasdaqGS: QLTI). http://photos.prnewswire.com/prnvar/20120409/MM84375LOGO Click here to learn more about the investigation: http://zlk.9nl.com/auxilium-pharmaceuticals-auxl, or...

2014-06-26 08:27:14

Accelerates Auxilium's Ongoing Transformation Into Leading North American Specialty Biopharmaceutical Company CHESTERBROOK, Pa. and VANCOUVER, Canada, June 26, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, and QLT Inc. (NASDAQ: QLTI) (TSX: QLT), a Canadian-based biotechnology company focused on developing innovative orphan ophthalmology products, today announced that they have entered into a definitive...

2014-06-25 16:26:44

LYNBROOK, N.Y., June 25, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, announced today that Swedish Orphan Biovitrum AB (Sobi) has filed for an extension of the label for XIAPEX (the EU trade name for collagenase clostridium histolyticum or CCH) with the European Medicines Agency (EMA) to include the indication of...

2014-06-25 08:31:00

STOCKHOLM and CHESTERBROOK, Pa., June 25, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. today announced that Sobi has filed for an extension of the label for Xiapex® (collagenase clostridium histolyticum) with the European Medicines Agency (EMA) to include the indication of Peyronie's disease. The filing is based on positive safety and efficacy outcome data from two double-blind placebo-controlled studies, IMPRESS I and II (The...

2014-06-11 08:28:34

CHESTERBROOK, Pa., June 11, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC ("Prasco") to introduce an Authorized Generic version of Testim(®) (testosterone gel). Prasco has product inventory available and has commenced shipping product. Testim and its Authorized Generic version are testosterone gels approved by the U.S. Food and Drug Administration to treat...

2014-06-02 16:26:58

CHESTERBROOK, Pa., June 2, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that James E. Fickenscher, Chief Financial Officer, is leaving the Company to pursue other interests. Mr. Fickenscher will continue in his current role through August 15, 2014. "The Board and I want to thank Jim for his nine years of service and important contributions to the evolution of Auxilium," said Adrian Adams,...

2014-05-30 08:25:45

CHESTERBROOK, Pa., May 30, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Jefferies Healthcare Conference to be held June 2-5, 2014 in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio Company at 10:00 a.m. ET on Tuesday, June...

2014-05-19 20:21:42

LYNBROOK, N.Y., May 19, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) in the EU, today announced that new analyses of data evaluating the use of XIAFLEX in adult men with Peyronie's disease were presented by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium) at the 2014 Annual...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'